BE2018C008I2 - - Google Patents

Download PDF

Info

Publication number
BE2018C008I2
BE2018C008I2 BE2018C008C BE2018C008C BE2018C008I2 BE 2018C008 I2 BE2018C008 I2 BE 2018C008I2 BE 2018C008 C BE2018C008 C BE 2018C008C BE 2018C008 C BE2018C008 C BE 2018C008C BE 2018C008 I2 BE2018C008 I2 BE 2018C008I2
Authority
BE
Belgium
Prior art keywords
represent
alkoxy
present
compounds
solvates
Prior art date
Application number
BE2018C008C
Other languages
English (en)
Dutch (nl)
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18980738&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2018C008(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of BE2018C008I2 publication Critical patent/BE2018C008I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
BE2018C008C 2001-04-27 2018-02-08 BE2018C008I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001132775 2001-04-27
PCT/JP2002/004279 WO2002088110A1 (fr) 2001-04-27 2002-04-26 Derives de quinoline ayant un groupe azolyle et derives de quinazoline

Publications (1)

Publication Number Publication Date
BE2018C008I2 true BE2018C008I2 (de) 2021-02-04

Family

ID=18980738

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2018C008C BE2018C008I2 (de) 2001-04-27 2018-02-08

Country Status (25)

Country Link
US (2) US6821987B2 (de)
EP (2) EP1652847B1 (de)
JP (1) JP2010077131A (de)
KR (1) KR100879669B1 (de)
CN (1) CN1273466C (de)
AT (1) ATE396988T1 (de)
AU (1) AU2002255284B2 (de)
BE (1) BE2018C008I2 (de)
BR (1) BRPI0209216B8 (de)
CA (1) CA2445333C (de)
DE (2) DE60208364T2 (de)
DK (1) DK1382604T3 (de)
ES (1) ES2256466T3 (de)
FR (1) FR18C1006I2 (de)
HK (1) HK1070649A1 (de)
IL (1) IL158459A0 (de)
MX (1) MXPA03009662A (de)
NL (1) NL300927I9 (de)
NO (2) NO326325B1 (de)
NZ (1) NZ529046A (de)
PL (1) PL209822B1 (de)
RU (1) RU2283841C2 (de)
TW (1) TWI324154B (de)
WO (1) WO2002088110A1 (de)
ZA (1) ZA200307861B (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200102090T2 (tr) * 1999-01-22 2002-01-21 Kirin Beer Kabushiki Kaisha Kinolin türevleri ve kinazolin türevleri.
WO2001047890A1 (fr) * 1999-12-24 2001-07-05 Kirin Beer Kabushiki Kaisha Quinoline, derives de la quinazoline et medicaments contenant ces substances
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
EP1777218B1 (de) * 2000-10-20 2008-12-31 Eisai R&D Management Co., Ltd. Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
DE60208364T2 (de) * 2001-04-27 2006-09-28 Kirin Beer K.K. Chinolinderivate mit einer azolylgruppe und chinazolinderivate
JP4342935B2 (ja) * 2001-06-22 2009-10-14 協和発酵キリン株式会社 肝細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
US7495104B2 (en) * 2001-10-17 2009-02-24 Kirin Beer Kabushiki Kaisha Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors
WO2003093238A1 (fr) * 2002-05-01 2003-11-13 Kirin Beer Kabushiki Kaisha Derives de quinoleine et derives de quinazoline inhibiteurs de l'autophosphorylation du recepteur du facteur stimulant la proliferation des macrophages
EP2280003B1 (de) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Verfahren zur Herstellung von Rezeptorkinase-Modulatoren
WO2004035572A1 (ja) * 2002-10-21 2004-04-29 Kirin Beer Kabushiki Kaisha Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形
WO2004039782A1 (ja) * 2002-10-29 2004-05-13 Kirin Beer Kabushiki Kaisha Ｆｌｔ３自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
WO2004060373A1 (ja) * 2002-12-27 2004-07-22 Santen Pharmaceutical Co., Ltd. 滲出型加齢黄斑変性治療剤
AU2004220548A1 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
ATE508747T1 (de) * 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
DK2210607T3 (da) * 2003-09-26 2011-12-12 Exelixis Inc N-[3-fluor-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid til behandling af kræft
EP1683785B1 (de) 2003-11-11 2013-10-16 Eisai R&D Management Co., Ltd. Harnstoffderivate und verfahren zu deren herstellung
US20050171172A1 (en) * 2003-11-13 2005-08-04 Ambit Biosciences Corporation Amide derivatives as PDGFR modulators
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
AU2005207946A1 (en) * 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
WO2006030826A1 (ja) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
CA2603748A1 (en) * 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
US20100105031A1 (en) * 2005-08-01 2010-04-29 Esai R & D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP1938842A4 (de) * 2005-09-01 2013-01-09 Eisai R&D Man Co Ltd Verfahren zur herstellung einer pharmazeutischen zusammensetzung mit verbesserten zerfallseigenschaften
JPWO2007052849A1 (ja) * 2005-11-07 2009-04-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質とｃ−ｋｉｔキナーゼ阻害物質との併用
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
JPWO2008001956A1 (ja) * 2006-06-29 2009-12-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝線維症治療剤
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
EP2119707B1 (de) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Zusammensetzung zur behandlung von nicht differenzierten formen von magenkrebsen
CA2697795C (en) 2007-08-29 2016-08-16 Methylgene Inc. Thieno[3,2,b]pyridinyl compounds as inhibitors of protein tyrosine kinase activity
JP5638244B2 (ja) 2007-11-09 2014-12-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質と抗腫瘍性白金錯体との併用
CN102036962B (zh) * 2008-01-29 2013-08-07 卫材R&D管理有限公司 血管生成抑制剂和紫杉烷的组合使用
EP2268623B9 (de) * 2008-03-17 2018-02-28 Ambit Biosciences Corporation Chinazolinderivate als raf-kinasemodulatoren und verwendungsverfahren
WO2010083414A1 (en) 2009-01-16 2010-07-22 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms therof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US7998973B2 (en) * 2009-11-13 2011-08-16 Aveo Pharmaceuticals, Inc. Tivozanib and temsirolimus in combination
KR101677790B1 (ko) 2010-06-25 2016-11-18 에자이 알앤드디 매니지먼트 가부시키가이샤 키나제 저해 작용을 갖는 화합물의 병용에 의한 항종양제
US20130225581A1 (en) * 2010-07-16 2013-08-29 Kyowa Hakko Kirin Co., Ltd Nitrogen-containing aromatic heterocyclic derivative
BR112013009701A2 (pt) 2010-10-27 2016-07-19 Novartis Ag regimes de dosagem para o tratamento de doença vascular ocular
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN102532116B (zh) * 2011-08-09 2015-01-21 武汉迈德森医药科技有限公司 抗肿瘤靶向治疗药物tivozanib的合成方法
CN102408411B (zh) * 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
CN102408418A (zh) * 2011-10-21 2012-04-11 武汉迈德森医药科技有限公司 Tivozanib酸性盐及其制备方法和晶型
EP2626073A1 (de) 2012-02-13 2013-08-14 Harmonic Pharma Verbindung zur Verwendung zur Prävention bzw. Behandlung einer neurogenerativen Erkrankung oder einer Erkrankung mit Phosphodiesterase (PDE4) -4-Aktivierung
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
RU2658601C2 (ru) 2013-05-14 2018-06-21 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Биомаркер для прогнозирования и оценки чувствительности субъектов с раком эндометрия к соединениям ленватиниба
SG10201708882TA (en) 2013-07-12 2017-12-28 Ophthotech Corp Methods for treating or preventing ophthalmological conditions
EP4089076A1 (de) 2014-08-28 2022-11-16 Eisai R&D Management Co., Ltd. Hochreines chinolinderivat und verfahren zum herstellen davon
EP3789027A1 (de) 2015-01-13 2021-03-10 Kyoto University Bosutinib, sunitinib, tivozanib, imatinib, nilotinib, rebastinib or bafetinib zur prävention und/oder behandlung von amyotropher lateralsklerose
RS65049B1 (sr) 2015-02-25 2024-02-29 Eisai R&D Man Co Ltd Metoda za suzbijanje gorčine derivata kinolina
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
BR112018006873A2 (pt) 2015-10-05 2018-11-06 The Trustees Of Columbia University In The City Of New York ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias
WO2018028591A1 (zh) 2016-08-09 2018-02-15 殷建明 一种喹啉衍生物及其用途
CN106478621B (zh) * 2016-09-30 2018-12-25 遵义医学院 喹啉或喹唑啉类衍生物、制备方法及其应用
JP7105774B2 (ja) 2016-12-01 2022-07-25 イグナイタ インコーポレイテッド がん治療のための方法
CN108341813B (zh) * 2017-01-24 2020-11-17 四川大学 取代的1-(异恶唑-3-基)-3-(3-氟-4-苯基)脲衍生物及其制备方法和用途
CN108530455B (zh) 2017-03-01 2021-01-12 北京赛特明强医药科技有限公司 脲取代的芳环连二噁烷并喹唑啉类化合物或药用盐或水合物及作为酪氨酸激酶抑制剂的应用
MX2019012847A (es) 2017-04-27 2022-01-07 Astrazeneca Ab Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
US11053223B2 (en) 2017-04-27 2021-07-06 Astrazeneca Ab Phenoxyquinazoline compounds and their use in treating cancer
CN109553612B (zh) * 2017-09-26 2021-09-03 广西梧州制药（集团）股份有限公司 一种吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途
US11479559B2 (en) 2018-02-11 2022-10-25 Beijing Scitech-Mq Pharmaceuticals Limited Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof
BR112021008606A2 (pt) 2018-11-05 2021-08-03 Aveo Pharmaceuticals, Inc. uso de tivozanibe para tratar indivíduos com câncer refratário
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2023096651A1 (en) 2021-11-26 2023-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treating bile duct cancers with tivozanib
WO2023228095A1 (en) 2022-05-24 2023-11-30 Daiichi Sankyo Company, Limited Dosage regimen of an anti-cdh6 antibody-drug conjugate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2728878B2 (ja) 1987-12-15 1998-03-18 大倉工業株式会社 中空押出成形板
DE69622183D1 (de) * 1995-11-07 2002-08-08 Kirin Brewery Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
JP4194678B2 (ja) 1997-11-28 2008-12-10 キリンファーマ株式会社 キノリン誘導体およびそれを含む医薬組成物
CZ299156B6 (cs) * 1997-12-22 2008-05-07 Bayer Corporation Substituované heterocyklické mocoviny, farmaceutické prípravky je obsahující a jejich použití
JP4403482B2 (ja) 1997-12-22 2010-01-27 バイエル コーポレイション 置換複素環尿素合成のための中間体およびその製造方法
TR200102090T2 (tr) * 1999-01-22 2002-01-21 Kirin Beer Kabushiki Kaisha Kinolin türevleri ve kinazolin türevleri.
WO2001047890A1 (fr) 1999-12-24 2001-07-05 Kirin Beer Kabushiki Kaisha Quinoline, derives de la quinazoline et medicaments contenant ces substances
JP2002030083A (ja) 2000-07-18 2002-01-29 Kirin Brewery Co Ltd Ｎ−（２−クロロ−４−｛［６−メトキシ−７−（３−ピリジルメトキシ）−４−キノリル］オキシ｝フェニル）−ｎ’−プロピルウレアの二塩酸塩
EP1777218B1 (de) * 2000-10-20 2008-12-31 Eisai R&D Management Co., Ltd. Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
DE60208364T2 (de) 2001-04-27 2006-09-28 Kirin Beer K.K. Chinolinderivate mit einer azolylgruppe und chinazolinderivate

Also Published As

Publication number Publication date
BRPI0209216B1 (pt) 2017-05-30
DE60226912D1 (de) 2008-07-10
NL300927I9 (nl) 2019-02-05
RU2003134376A (ru) 2005-04-20
US20040229876A1 (en) 2004-11-18
NL300927I1 (nl) 2018-12-04
EP1652847A1 (de) 2006-05-03
US20030087907A1 (en) 2003-05-08
DE60208364T2 (de) 2006-09-28
HK1070649A1 (en) 2005-06-24
DE60208364D1 (de) 2006-02-02
ATE396988T1 (de) 2008-06-15
TWI324154B (de) 2010-05-01
KR20040015143A (ko) 2004-02-18
ZA200307861B (en) 2004-10-08
AU2002255284B2 (en) 2007-10-04
WO2002088110A1 (fr) 2002-11-07
US6821987B2 (en) 2004-11-23
CN1273466C (zh) 2006-09-06
PL367105A1 (en) 2005-02-21
EP1652847B1 (de) 2008-05-28
IL158459A0 (en) 2004-05-12
FR18C1006I1 (fr) 2018-03-16
MXPA03009662A (es) 2004-12-06
NO2018005I1 (no) 2018-02-05
EP1382604B1 (de) 2005-12-28
CA2445333A1 (en) 2002-11-07
KR100879669B1 (ko) 2009-01-21
CN1543459A (zh) 2004-11-03
NZ529046A (en) 2005-10-28
BR0209216A (pt) 2004-07-06
EP1382604A1 (de) 2004-01-21
ES2256466T3 (es) 2006-07-16
BRPI0209216B8 (pt) 2021-05-25
DK1382604T3 (da) 2006-04-18
US7211587B2 (en) 2007-05-01
NO326325B1 (no) 2008-11-10
FR18C1006I2 (fr) 2019-03-01
NO20034595D0 (no) 2003-10-14
RU2283841C2 (ru) 2006-09-20
EP1652847A3 (de) 2006-08-02
CA2445333C (en) 2011-03-22
PL209822B1 (pl) 2011-10-31
NO20034595L (no) 2003-12-19
JP2010077131A (ja) 2010-04-08
EP1382604A4 (de) 2004-09-08

Similar Documents

Publication Publication Date Title
BE2018C008I2 (de)
IL159418A0 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
HK1019878A1 (en) Total synthesis of antitumor acylfulvenes.
DE69529619D1 (en) Pyrimidinylpyrazolderivate
HK1057215A1 (en) Benzo ÄbÄthiophene derivatives and process for producing the same
FI952420A (fi) Glukopyranosidibentsotiofeenit
HUP0301561A2 (hu) Triazintrion-szulfoxidok alkalmazása kokcidiózis elleni készítmények elżállítására
EP1251129A4 (de) Pyrimidinderivate mit antitumor-wirkung
EP1466900A4 (de) 2-substituierte vitamin-d-derivate